| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Change in right-of-use assets | NaN | 255,616 | 103,339 | 79,045 |
| Net income | 38,601,000 | 14,020,141 | 108,562,980 | 40,471,879 |
| Depreciation | NaN | 294,096 | 161,917 | 220,987 |
| Stock-based compensation | 4,582,000 | 3,589,024 | 4,065,541 | 6,177,435 |
| Amortization of intangible | NaN | 10,139,555 | 3,628,549 | 103,896 |
| Depreciation and amortization | 10,544,000 | NaN | NaN | NaN |
| Change in contingent consideration | -4,199,000 | -4,101,000 | -2,400,000 | NaN |
| Change in fair value of marketable securities | 3,546,000 | -2,273,091 | -3,090,909 | NaN |
| Deferred income taxes | 12,964,000 | 33,889,802 | -59,686,802 | NaN |
| Amortization of debt finance costs | NaN | 398,000 | NaN | NaN |
| Other | -672,000 | 111,230 | -363,230 | NaN |
| Gain on liquidation of foreign entity | NaN | 86,000 | NaN | NaN |
| Decrease in operating lease liabilities | NaN | -149,567 | -76,666 | -81,767 |
| Decrease (increase) in account receivables | -16,445,000 | 12,395,714 | 87,270,234 | -8,741,948 |
| (increase) decrease in inventory | 1,015,000 | 800,120 | 642,977 | 2,034,903 |
| Increase in prepaid expenses and other assets | 2,257,000 | 1,363,757 | -1,108,444 | 1,805,687 |
| Increase in accounts payable | 4,943,000 | -7,265,271 | 6,499,113 | 4,095,158 |
| (decrease) increase in accrued expenses and other liabilities | -50,622,000 | 52,279,697 | 54,730,977 | -6,239,674 |
| Payment of contingent consideration liabilities | 220,000 | 61,000 | NaN | NaN |
| Net cash provided by operating activities | 42,382,000 | 94,461,181 | 30,856,502 | 49,728,317 |
| Acquisitions of businesses, net of cash acquired | NaN | -1,490,965 | 310,001,965 | NaN |
| Investment in equity securities | NaN | 0 | 5,000,000 | NaN |
| Purchase of short-term investments | 0 | 73,935 | 9,605,591 | 38,272,474 |
| Maturity of short-term investments | 3,694,000 | 3,600,113 | 33,792,887 | 17,900,000 |
| Purchase of equipment | 729,000 | 1,720,104 | 505,774 | 34,122 |
| Net cash provided by (used in) investing activities | 2,965,000 | 3,297,039 | -291,320,443 | -20,406,596 |
| Proceeds from sale of common stock from public offering, net | NaN | -600 | 3,891 | 82,366,709 |
| Proceeds from senior convertible notes | NaN | 0 | 150,000,000 | NaN |
| Proceeds from sale of common stock from at-the-market program, net | 0 | 1,026,427 | 0 | 6,761,573 |
| Repurchase of common stock | 11,092,000 | NaN | NaN | NaN |
| Payment of employee withholding taxes on vested restricted stock units | 1,527,000 | 257,440 | 464,088 | 1,266,472 |
| Proceeds from exercise of stock options | 1,179,000 | 3,592,986 | 1,322,690 | 1,473,324 |
| Payment of debt issuance costs associated with the convertible notes | NaN | 5,446,623 | 282,377 | NaN |
| Payment of contingent consideration liabilities | 522,000 | 189,000 | NaN | NaN |
| Rou financing lease fees | 135,000 | 138,808 | 49,192 | NaN |
| Net cash (used in) provided by financing activities | -12,097,000 | -1,413,058 | 150,530,924 | 89,335,134 |
| Foreign exchange effect on cash | -1,333 | NaN | 276 | 1,057 |
| Net increase in cash and cash equivalents | 33,250,000 | 96,343,829 | -109,932,741 | 118,657,912 |
| Cash, cash equivalents and restricted cash - beginning of period | 145,825,000 | 49,481,309 | 40,756,138 | NaN |
| Cash, cash equivalents and restricted cash - end of period | 179,075,000 | 145,825,000 | 49,481,309 | NaN |
CorMedix Inc. (CRMD)
CorMedix Inc. (CRMD)